{"gene":"F13A1","run_date":"2026-04-28T17:46:03","timeline":{"discoveries":[{"year":1974,"finding":"Factor XIII A-subunit is activated by thrombin cleavage, releasing an activation peptide from the amino terminus.","method":"Amino acid sequence analysis of tryptic peptides and activation peptide isolation","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — direct biochemical sequencing of activation peptide, foundational study with 223 citations","pmids":["4811064"],"is_preprint":false},{"year":1986,"finding":"The A subunit of human factor XIII (F13A1) is a 731-amino acid protein containing a catalytic triad active site with the sequence Tyr-Gly-Gln-Cys-Trp, identical to that of tissue transglutaminase; thrombin cleaves it at two sites — activation at the N-terminus and inactivation after Lys-513.","method":"cDNA cloning from human placenta library, amino acid sequencing by automated sequenator, cyanogen bromide peptide analysis","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 — complete primary structure determined by cDNA + direct protein sequencing, replicated by two independent labs in same year","pmids":["3026437","2877456","2877457"],"is_preprint":false},{"year":1988,"finding":"The F13A1 gene spans >160 kb and contains 15 exons separated by 14 introns; functionally distinct regions (activation peptide, active-site cysteine, calcium-binding regions, thrombin inactivation site) are each encoded by separate exons, suggesting domain-level structural organization.","method":"Genomic library screening, restriction mapping, Southern blotting, DNA sequencing","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — complete gene structure determination with functional domain mapping","pmids":["2901091"],"is_preprint":false},{"year":1994,"finding":"The three-dimensional crystal structure of human factor XIII zymogen at 2.8-Å resolution reveals that each A-subunit chain folds into four sequential domains; a catalytic triad (Cys-His-Asp) reminiscent of cysteine proteases is located in the core domain; the amino-terminal activation peptide of each subunit crosses the dimer interface and partially occludes the catalytic cavity of the second subunit, preventing substrate access in the zymogen. Thrombin cleavage and calcium binding are proposed to open the active site.","method":"X-ray crystallography of recombinant human factor XIII at 2.8-Å resolution","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with mechanistic interpretation, 303 citations","pmids":["7913750"],"is_preprint":false},{"year":1994,"finding":"Factor XIII uses a cysteine proteinase-like catalytic triad (Cys-His-Asp) to catalyze transglutaminase crosslinking reactions; structural comparison shows active site architecture is shared with cysteine proteinases despite different overall fold, suggesting convergent or divergent evolution.","method":"X-ray crystallography, structural comparison of active site residues","journal":"Protein science : a publication of the Protein Society","confidence":"High","confidence_rationale":"Tier 1 — crystal structure with active-site mechanistic analysis, 126 citations","pmids":["7920263"],"is_preprint":false},{"year":1998,"finding":"The refined 2.1-Å crystal structure of human cellular factor XIII zymogen identifies two non-proline cis peptide bonds: one between Arg310 and Tyr311 near the active site cysteine (Cys314), and one between Gln425 and Phe426 at the dimerization interface, suggesting these structural elements are important for catalytic function and dimer stability.","method":"X-ray crystallography refined to R-factor 18.3% at 2.1-Å resolution","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 — high-resolution crystal structure with structural functional interpretation, 128 citations","pmids":["9515726"],"is_preprint":false},{"year":2011,"finding":"An intronic mutation in intron 1 of F13A1 (Int1+12C>A) causes mild FXIII deficiency by reducing protein binding at an Sp1 site; Sp1 was shown to regulate F13A1 transcription via the first 951 bp of intron 1, and co-transfection with Sp1 restored expression, establishing intron 1 as a regulatory element.","method":"Luciferase reporter assays in U937 cells, electrophoretic mobility shift assay (EMSA), Sp1 co-transfection, direct sequencing","journal":"Journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal in vitro methods (reporter + EMSA + co-transfection), single lab","pmids":["21512576"],"is_preprint":false},{"year":2015,"finding":"FXIIIa-dependent retention of red blood cells in contracting clots is mediated specifically by fibrin α-chain crosslinking; FXIIIa does not directly crosslink RBCs to fibrin. RBC retention was lost when α-chain crosslinking sites were absent but not when γ-chain crosslinking sites were absent, and was independent of FXIIIa substrates α2-antiplasmin, thrombin-activatable fibrinolysis inhibitor, or fibronectin.","method":"Real-time microscopy of clot contraction, fibrin band-shift assays, flow cytometry, clots from mice deficient in specific FXIIIa substrates, FXIIIa inhibition at concentrations selectively blocking α- vs γ-chain crosslinking","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1-2 — multiple orthogonal approaches including genetic knockouts and selective inhibition, mechanistic dissection of crosslinking specificity, 137 citations","pmids":["26324704"],"is_preprint":false},{"year":2019,"finding":"ZED3197, a peptidomimetic inhibitor, potently and selectively inhibits FXIIIa transglutaminase activity (transamidation and isopeptidase assays) with selectivity over other human transglutaminases; it inhibits fibrin crosslinking in whole blood thromboelastometry and reduces clot weight in a rabbit venous stasis model without prolonging bleeding time, demonstrating that FXIIIa inhibition can dissociate antithrombotic effect from bleeding risk.","method":"Transamidation and isopeptidase biochemical assays, rotational thromboelastometry in whole human blood, rabbit venous stasis/reperfusion in vivo model","journal":"Journal of thrombosis and haemostasis : JTH","confidence":"High","confidence_rationale":"Tier 1-2 — in vitro enzymatic assays plus in vivo pharmacological validation, multiple methods","pmids":["31578814"],"is_preprint":false},{"year":2025,"finding":"RUNX1 transcription factor directly regulates F13A1 transcription in megakaryocytes and platelets; RUNX1 overexpression increased and siRNA knockdown decreased F13A1 promoter activity and protein. F13A1 knockdown impaired clot contraction, reduced FXIII-A surface expression, decreased myosin light chain phosphorylation, and reduced αIIbβ3 activation (PAC1 binding), establishing F13A1 as a downstream effector of RUNX1 in platelet clot contraction.","method":"Promoter luciferase assays in HEL cells, siRNA knockdown of RUNX1 and F13A1, clot contraction assays, flow cytometry (surface FXIII-A, PAC1), myosin light chain phosphorylation assays, human CD34+-derived megakaryocytes","journal":"Research and practice in thrombosis and haemostasis","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (reporter, KD, functional clot assay, phosphorylation) across cell lines and primary megakaryocytes","pmids":["39995753"],"is_preprint":false},{"year":2025,"finding":"F13A1 in macrophages directly interacts with pyruvate kinase M2 (PKM2), promoting PKM2 dimerization in a calcium-dependent manner; dimerized PKM2 translocates to the nucleus and upregulates IL-1β via the PKM2/HIF1A axis, driving macrophage pro-inflammatory activation and the Warburg effect in MASH. F13A1 expression in macrophages is induced by lipid-stressed hepatocytes through a sphingosine-1-phosphate (S1P)-dependent mechanism.","method":"Co-immunoprecipitation (F13A1-PKM2 interaction), siRNA silencing of F13A1 in vivo and in vitro, nuclear translocation assays, IL-1β expression assays, PKM2 activator (DASA-58) pharmacological rescue, single-nucleus transcriptomic datasets, murine MASH models","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP plus functional rescue with pharmacological PKM2 activator and in vivo silencing, single lab","pmids":["41417477"],"is_preprint":false},{"year":1998,"finding":"Factor XIIIa is expressed in CD14+-derived dendritic cells but not in CD1a+-derived dendritic cells, establishing lineage-specific expression of F13A1 within the dendritic cell compartment differentiated from CD34+ progenitors.","method":"Semiquantitative RT-PCR and phenotypic analysis of two DC subpopulations generated in vitro from CD34+ progenitors","journal":"Journal of immunology (Baltimore, Md. : 1950)","confidence":"Medium","confidence_rationale":"Tier 3 — RT-PCR-based localization with cellular phenotype characterization, 314 citations but single method for F13A1 specifically","pmids":["9469423"],"is_preprint":false},{"year":2013,"finding":"FXIII-A is overexpressed in nasal polyps and is produced predominantly by CD68+/CD163+ M2 macrophages; FXIII-A levels correlate with M2 macrophage markers, implicating macrophage-derived FXIII-A in excessive fibrin crosslinking and tissue remodeling in chronic rhinosinusitis with nasal polyps.","method":"Real-time PCR, ELISA, immunohistochemistry, immunofluorescence co-staining with macrophage markers in human sinonasal tissue","journal":"The Journal of allergy and clinical immunology","confidence":"Medium","confidence_rationale":"Tier 3 — multiple protein detection methods establishing cellular source, no functional KO/KD experiment, 112 citations","pmids":["23541322"],"is_preprint":false}],"current_model":"F13A1 encodes the A-subunit of coagulation factor XIII, a transglutaminase zymogen that circulates as an A2B2 tetramer; upon thrombin cleavage of its activation peptide and calcium binding, the active site Cys314 (within a Cys-His-Asp catalytic triad structurally analogous to cysteine proteases) is exposed, enabling covalent γ-glutamyl-ε-lysyl crosslinking of fibrin (primarily via α-chain crosslinking to retain RBCs in clots), and the protein also functions intracellularly in macrophages and platelets where it interacts with PKM2 to drive inflammatory signaling and is transcriptionally regulated by RUNX1 in megakaryocytes/platelets to support clot contraction."},"narrative":{"teleology":[{"year":1974,"claim":"Establishing that factor XIII is a thrombin-activated zymogen resolved how transglutaminase activity is regulated in coagulation, identifying the activation peptide as the gating element.","evidence":"Amino acid sequencing of tryptic peptides and isolation of activation peptide from purified factor XIII","pmids":["4811064"],"confidence":"High","gaps":["Mechanism by which activation peptide removal triggers catalytic competence was unknown","Calcium requirement not yet defined"]},{"year":1986,"claim":"Complete primary structure determination revealed F13A1 as a 731-residue transglutaminase sharing the Tyr-Gly-Gln-Cys-Trp active-site motif with tissue transglutaminase, placing it firmly in the transglutaminase family and identifying a second thrombin inactivation site at Lys-513.","evidence":"cDNA cloning from human placenta, automated amino acid sequencing, cyanogen bromide peptide analysis by two independent laboratories","pmids":["3026437","2877456","2877457"],"confidence":"High","gaps":["Three-dimensional structure and spatial arrangement of active-site residues unknown","Functional significance of inactivation cleavage at Lys-513 not tested"]},{"year":1988,"claim":"Mapping the gene structure showed that functionally distinct domains (activation peptide, catalytic cysteine, calcium-binding region) reside on separate exons, providing a framework for understanding disease-causing mutations and evolutionary modularity.","evidence":"Genomic library screening, restriction mapping, Southern blotting, and DNA sequencing of the >160 kb F13A1 locus","pmids":["2901091"],"confidence":"High","gaps":["Promoter and transcriptional regulatory elements not characterized","Intronic regulatory sequences not explored"]},{"year":1994,"claim":"Crystal structures of the zymogen resolved how the activation peptide from one subunit crosses the dimer interface to occlude the partner's catalytic cavity, explaining why thrombin cleavage and calcium are both required for activation, and revealed a Cys-His-Asp catalytic triad convergently similar to cysteine proteases.","evidence":"X-ray crystallography at 2.8 Å resolution of recombinant human factor XIII zymogen with structural comparison to cysteine proteinases","pmids":["7913750","7920263"],"confidence":"High","gaps":["No structure of the fully activated enzyme or enzyme–substrate complex","Conformational pathway from zymogen to active form not visualized"]},{"year":1998,"claim":"Higher-resolution refinement identified non-proline cis peptide bonds near the active site and dimer interface, pinpointing structural features critical for catalysis and A₂ dimer stability, while parallel studies showed lineage-restricted expression in CD14⁺-derived dendritic cells, broadening F13A1 function beyond coagulation.","evidence":"X-ray crystallography at 2.1 Å resolution; RT-PCR-based lineage analysis of DC subpopulations from CD34⁺ progenitors","pmids":["9515726","9469423"],"confidence":"High","gaps":["Functional role of cis peptide bonds not tested by mutagenesis","Function of F13A1 in dendritic cells not determined"]},{"year":2011,"claim":"Identification of Sp1-dependent transcriptional regulation through intron 1 provided the first mechanistic explanation for how non-coding mutations cause mild FXIII deficiency.","evidence":"Luciferase reporter assays in U937 cells, EMSA, and Sp1 co-transfection rescue for an Int1+12C>A patient mutation","pmids":["21512576"],"confidence":"Medium","gaps":["No chromatin-level or in vivo confirmation of Sp1 regulation","Other intronic regulatory elements not surveyed","Single patient mutation studied"]},{"year":2013,"claim":"Demonstrating that M2 (CD68⁺/CD163⁺) macrophages are the principal cellular source of FXIII-A in inflamed tissue linked the transglutaminase to tissue remodeling beyond plasma clot formation.","evidence":"Real-time PCR, ELISA, immunohistochemistry, and co-immunofluorescence in human nasal polyp tissue","pmids":["23541322"],"confidence":"Medium","gaps":["No knockdown or knockout to prove functional contribution in tissue remodeling","Mechanism of FXIII-A action in tissue not defined"]},{"year":2015,"claim":"Dissecting FXIIIa substrate specificity showed that fibrin α-chain crosslinking — not γ-chain crosslinking or other substrates — is the specific mechanism retaining red blood cells in contracting clots, redefining the functional hierarchy among FXIIIa crosslinking activities.","evidence":"Real-time clot contraction microscopy, selective FXIIIa inhibition, flow cytometry, and clots from mice lacking individual FXIIIa substrates","pmids":["26324704"],"confidence":"High","gaps":["Structural basis for α-chain crosslinking's unique role in RBC retention unknown","Whether α-chain crosslinking specificity is relevant in arterial versus venous thrombi not addressed"]},{"year":2019,"claim":"Pharmacological proof-of-concept with the selective inhibitor ZED3197 demonstrated that FXIIIa transglutaminase activity can be targeted to reduce venous thrombosis without increasing bleeding, separating antithrombotic efficacy from hemostatic risk.","evidence":"Biochemical transamidation/isopeptidase assays, whole-blood thromboelastometry, rabbit venous stasis model","pmids":["31578814"],"confidence":"High","gaps":["No data in arterial thrombosis models","Long-term safety and wound healing impact not assessed","Mechanism explaining preserved hemostasis despite FXIIIa inhibition not fully elucidated"]},{"year":2025,"claim":"Two studies expanded F13A1's mechanistic scope: RUNX1 was identified as a direct transcriptional regulator of F13A1 in megakaryocytes linking it to integrin activation and clot contraction, while in macrophages F13A1 was shown to directly interact with PKM2 to drive pro-inflammatory reprogramming via the PKM2/HIF1α/IL-1β axis.","evidence":"Promoter reporters, siRNA knockdown of RUNX1/F13A1, clot contraction and PAC1/MLC phosphorylation assays in HEL cells and primary megakaryocytes; Co-IP of F13A1–PKM2, DASA-58 pharmacological rescue, in vivo silencing in murine MASH models","pmids":["39995753","41417477"],"confidence":"High","gaps":["RUNX1-F13A1 axis not validated in vivo with RUNX1-deficient platelets","F13A1–PKM2 interaction awaits structural characterization","Whether F13A1 transglutaminase activity or a scaffolding role drives PKM2 dimerization is unresolved"]},{"year":null,"claim":"No structure of fully activated FXIIIa in complex with fibrin or PKM2 substrates exists, and the intracellular activation mechanism of F13A1 in platelets and macrophages (in the absence of thrombin) remains undefined.","evidence":"","pmids":[],"confidence":"High","gaps":["No activated FXIIIa–substrate co-crystal structure","Thrombin-independent intracellular activation mechanism unknown","Relative contribution of enzymatic versus scaffolding functions in immune cells not delineated"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,3,4,7,8]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,3,4,7,8]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,7,8]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[9,10]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[10]}],"pathway":[{"term_id":"R-HSA-109582","term_label":"Hemostasis","supporting_discovery_ids":[0,1,3,7,8,9]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[10,11,12]}],"complexes":[],"partners":["PKM2","RUNX1","SP1"],"other_free_text":[]},"mechanistic_narrative":"F13A1 encodes the catalytic A-subunit of coagulation factor XIII, a transglutaminase zymogen that circulates as an A₂ homodimer and is activated by thrombin cleavage of an N-terminal activation peptide followed by calcium-dependent conformational opening of a Cys-His-Asp catalytic triad structurally analogous to cysteine proteases [PMID:4811064, PMID:7913750, PMID:7920263]. Activated FXIIIa catalyzes γ-glutamyl-ε-lysyl isopeptide crosslinking of fibrin, with α-chain crosslinking specifically required for red blood cell retention during clot contraction, while selective pharmacological inhibition of FXIIIa reduces thrombus formation without prolonging bleeding time [PMID:26324704, PMID:31578814]. In megakaryocytes and platelets, F13A1 is transcriptionally regulated by RUNX1 and functions as a downstream effector supporting integrin αIIbβ3 activation and myosin light chain phosphorylation during clot contraction [PMID:39995753]. Beyond hemostasis, intracellular F13A1 in macrophages interacts with PKM2 in a calcium-dependent manner, promoting PKM2 dimerization and nuclear translocation to drive IL-1β expression via the HIF1α axis during pro-inflammatory activation [PMID:41417477]."},"prefetch_data":{"uniprot":{"accession":"P00488","full_name":"Coagulation factor XIII A chain","aliases":["Protein-glutamine gamma-glutamyltransferase A chain","Transglutaminase A chain"],"length_aa":732,"mass_kda":83.3,"function":"Factor XIII is activated by thrombin and calcium ion to a transglutaminase that catalyzes the formation of gamma-glutamyl-epsilon-lysine cross-links between fibrin chains, thus stabilizing the fibrin clot. Also cross-link alpha-2-plasmin inhibitor, or fibronectin, to the alpha chains of fibrin","subcellular_location":"Cytoplasm; Secreted","url":"https://www.uniprot.org/uniprotkb/P00488/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/F13A1","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/F13A1","total_profiled":1310},"omim":[{"mim_id":"613225","title":"FACTOR XIII, A SUBUNIT, DEFICIENCY OF","url":"https://www.omim.org/entry/613225"},{"mim_id":"612582","title":"CHROMOSOME 6pter-p24 DELETION SYNDROME","url":"https://www.omim.org/entry/612582"},{"mim_id":"608446","title":"MYOCARDIAL INFARCTION, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/608446"},{"mim_id":"600585","title":"TRANSGLUTAMINASE 4; TGM4","url":"https://www.omim.org/entry/600585"},{"mim_id":"600511","title":"SCHIZOPHRENIA 3; SCZD3","url":"https://www.omim.org/entry/600511"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":217.7},{"tissue":"placenta","ntpm":459.5}],"url":"https://www.proteinatlas.org/search/F13A1"},"hgnc":{"alias_symbol":[],"prev_symbol":["F13A"]},"alphafold":{"accession":"P00488","domains":[{"cath_id":"2.60.40.10","chopping":"31-185","consensus_level":"high","plddt":96.7092,"start":31,"end":185},{"cath_id":"3.90.260.10","chopping":"200-502","consensus_level":"medium","plddt":93.6025,"start":200,"end":502},{"cath_id":"2.60.40.10","chopping":"520-628","consensus_level":"high","plddt":92.0452,"start":520,"end":628},{"cath_id":"2.60.40.10","chopping":"635-727","consensus_level":"high","plddt":95.6316,"start":635,"end":727}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P00488","model_url":"https://alphafold.ebi.ac.uk/files/AF-P00488-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P00488-F1-predicted_aligned_error_v6.png","plddt_mean":90.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=F13A1","jax_strain_url":"https://www.jax.org/strain/search?query=F13A1"},"sequence":{"accession":"P00488","fasta_url":"https://rest.uniprot.org/uniprotkb/P00488.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P00488/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P00488"}},"corpus_meta":[{"pmid":"2903011","id":"PMC_2903011","title":"Localization of the coagulation factor XIII A subunit gene (F13A) to chromosome bands 6p24----p25.","date":"1988","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2903011","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2888553","id":"PMC_2888553","title":"Suggestion of linkage of a major locus for nonsyndromic orofacial cleft with F13A and tentative assignment to chromosome 6.","date":"1987","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2888553","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2897163","id":"PMC_2897163","title":"Extensive DNA polymorphism at the factor XIIIa (F13A) locus and linkage to HLA.","date":"1988","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2897163","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26654441","id":"PMC_26654441","title":"Coagulation Factor XIIIA (F13A1): Novel Perspectives in Treatment and Pharmacogenetics.","date":"2016","source":"Current pharmaceutical design","url":"https://pubmed.ncbi.nlm.nih.gov/26654441","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1928103","id":"PMC_1928103","title":"Tight linkage of the gene for spinocerebellar ataxia to D6S89 on the short arm of chromosome 6 in a kindred for which close linkage to both HLA and F13A1 is excluded.","date":"1991","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/1928103","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2858156","id":"PMC_2858156","title":"A structural locus for coagulation factor XIIIA (F13A) is located distal to the HLA region on chromosome 6p in man.","date":"1985","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2858156","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31578814","id":"PMC_31578814","title":"Novel inhibitor ZED3197 as potential drug candidate in anticoagulation targeting coagulation FXIIIa (F13a).","date":"2019","source":"Journal of thrombosis and haemostasis : JTH","url":"https://pubmed.ncbi.nlm.nih.gov/31578814","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7665157","id":"PMC_7665157","title":"Genetic mapping of F13A to BTA23 by sperm typing: difference in recombination rate between bulls in the DYA-PRL interval.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7665157","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6149187","id":"PMC_6149187","title":"The gene for coagulation factor XIII a subunit (F13A) is distal to HLA on chromosome 6.","date":"1984","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/6149187","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33167412","id":"PMC_33167412","title":"Transglutaminases and Obesity in Humans: Association of F13A1 to Adipocyte Hypertrophy and Adipose Tissue Immune Response.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33167412","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24889649","id":"PMC_24889649","title":"Eight novel F13A1 gene missense mutations in patients with mild FXIII deficiency: in silico analysis suggests changes in FXIII-A subunit structure/function.","date":"2014","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/24889649","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7999643","id":"PMC_7999643","title":"Swiss population data on three tetrameric short tandem repeat loci--VWA, HUMTHO1, and F13A1--derived using multiplex PCR and laser fluorescence detection.","date":"1994","source":"International journal of legal medicine","url":"https://pubmed.ncbi.nlm.nih.gov/7999643","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34859078","id":"PMC_34859078","title":"Platelet Phenotype Analysis of COVID-19 Patients Reveals Progressive Changes in the Activation of Integrin αIIbβ3, F13A1, the SARS-CoV-2 Target EIF4A1 and Annexin A5.","date":"2021","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34859078","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34066760","id":"PMC_34066760","title":"Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34066760","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33221826","id":"PMC_33221826","title":"F13A1 transglutaminase expression in human adipose tissue increases in acquired excess weight and associates with inflammatory status of adipocytes.","date":"2020","source":"International journal of obesity (2005)","url":"https://pubmed.ncbi.nlm.nih.gov/33221826","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28520207","id":"PMC_28520207","title":"Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A2.","date":"2017","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/28520207","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25821496","id":"PMC_25821496","title":"Xueshuan Xinmaining Tablet Treats Blood Stasis through Regulating the Expression of F13a1, Car1, and Tbxa2r.","date":"2015","source":"Evidence-based complementary and alternative medicine : eCAM","url":"https://pubmed.ncbi.nlm.nih.gov/25821496","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30223472","id":"PMC_30223472","title":"F13A1 Gene Variant (V34L) and Residual Circulating FXIIIA Levels Predict Short- and Long-Term Mortality in Acute Myocardial Infarction after Coronary Angioplasty.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30223472","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22565190","id":"PMC_22565190","title":"Androgen levels and metabolic parameters are associated with a genetic variant of F13A1 in women with polycystic ovary syndrome.","date":"2012","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/22565190","citation_count":16,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2860058","id":"PMC_2860058","title":"Linkage between the loci for mitochondrial malic enzyme (ME2) and coagulation factor XIIIA subunit (F13A).","date":"1985","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2860058","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31340840","id":"PMC_31340840","title":"Phenotype and genotype of FXIII deficiency in two unrelated probands: identification of a novel F13A1 large deletion mediated by complex rearrangement.","date":"2019","source":"Orphanet journal of rare diseases","url":"https://pubmed.ncbi.nlm.nih.gov/31340840","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29657559","id":"PMC_29657559","title":"Activation peptide of the coagulation factor XIII (AP-F13A1) as a new biomarker for the screening of colorectal cancer.","date":"2018","source":"Clinical proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/29657559","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8001915","id":"PMC_8001915","title":"Genetic studies on the Senegal population. II. Polymorphisms of the plasma proteins F13A, F13B, ORM1, AHSG, C6, C7, and APOC2.","date":"1994","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/8001915","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21512576","id":"PMC_21512576","title":"Homozygous intronic mutation leading to inefficient transcription combined with a novel frameshift mutation in F13A1 gene causes FXIII deficiency.","date":"2011","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21512576","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29363996","id":"PMC_29363996","title":"Polymorphisms of F2, PROC, PROZ, and F13A1 Genes are Associated With Recurrent Spontaneous Abortion in Chinese Han Women.","date":"2018","source":"Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/29363996","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24286209","id":"PMC_24286209","title":"Severe congenital factor XIII deficiency caused by novel W187X and G273V mutations in the F13A gene; diagnosis and classification according to the ISTH/SSC guidelines.","date":"2013","source":"Haemophilia : the official journal of the World Federation of Hemophilia","url":"https://pubmed.ncbi.nlm.nih.gov/24286209","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27081562","id":"PMC_27081562","title":"Characterization of a novel large deletion caused by double-stranded breaks in 6-bp microhomologous sequences of intron 11 and 12 of the F13A1 gene.","date":"2016","source":"Human genome variation","url":"https://pubmed.ncbi.nlm.nih.gov/27081562","citation_count":8,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2900213","id":"PMC_2900213","title":"Analysis for linkage between F13A and three chromosome 6 marker loci: evidence for 6pter:F13A:HLA:GLO1:cen gene order.","date":"1988","source":"Human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/2900213","citation_count":7,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39601163","id":"PMC_39601163","title":"Single-cell dissection reveals immunosuppressive F13A1+ macrophage as a hallmark for multiple primary lung cancers.","date":"2024","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39601163","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2312127","id":"PMC_2312127","title":"Formal and population genetics of F13A and FUCA1 polymorphisms in northern Portugal.","date":"1990","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/2312127","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25004025","id":"PMC_25004025","title":"Novel and recurrent mutations in the F13A1 gene in unrelated Korean patients with congenital factor XIII deficiency.","date":"2015","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/25004025","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23508224","id":"PMC_23508224","title":"A common F13A1 intron 1 variant IVS1+12(A) is associated with mild FXIII deficiency in Caucasian population.","date":"2013","source":"Annals of hematology","url":"https://pubmed.ncbi.nlm.nih.gov/23508224","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32060721","id":"PMC_32060721","title":"Factor XIII deficiency in two Spanish families with a novel variant in gene F13A1 detected by next-generation sequencing; symptoms and clinical management.","date":"2020","source":"Journal of thrombosis and thrombolysis","url":"https://pubmed.ncbi.nlm.nih.gov/32060721","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30935919","id":"PMC_30935919","title":"Identification of novel pathogenic F13A1 mutation and novel NBEAL2 gene missense mutation in a pedigree with hereditary congenital factor XIII deficiency.","date":"2019","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/30935919","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28978253","id":"PMC_28978253","title":"Coagulation F13A1 V34L, fibrinogen and homocysteine versus conventional risk factors in the pathogenesis of MI in young persons.","date":"2017","source":"Acta cardiologica","url":"https://pubmed.ncbi.nlm.nih.gov/28978253","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37006978","id":"PMC_37006978","title":"Genetic Spectrum in F13A1 Detected by Next-Generation Sequencing Among North Indian Patients with FXIII Deficiency.","date":"2022","source":"Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion","url":"https://pubmed.ncbi.nlm.nih.gov/37006978","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11236860","id":"PMC_11236860","title":"Diversity of two short tandem repeat loci (CD4 and F13A1) in three Brazilian ethnic groups.","date":"2000","source":"Human biology","url":"https://pubmed.ncbi.nlm.nih.gov/11236860","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41417477","id":"PMC_41417477","title":"F13A1-Mediated Macrophage Activation Promotes MASH Progression via the PKM2/HIF1A Pathway.","date":"2025","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/41417477","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10686499","id":"PMC_10686499","title":"Allelic affinities between the F13A common gene products inferred by the analysis of an (AAAG)n STR polymorphism within the 5' untranslated region.","date":"2000","source":"Human heredity","url":"https://pubmed.ncbi.nlm.nih.gov/10686499","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41177109","id":"PMC_41177109","title":"Plasma extracellular vesicle proteomics identifies FN1/F13A1-TGF-β pathway as the major signaling pathway associated with persistent atrial fibrillation.","date":"2025","source":"Journal of pharmaceutical and biomedical analysis","url":"https://pubmed.ncbi.nlm.nih.gov/41177109","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1969626","id":"PMC_1969626","title":"RFLP in human F13A gene.","date":"1990","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/1969626","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39995753","id":"PMC_39995753","title":"Transcription factor RUNX1 regulates coagulation factor XIII-A (F13A1): decreased platelet-megakaryocyte F13A1 expression and clot contraction in RUNX1 haplodeficiency.","date":"2025","source":"Research and practice in thrombosis and haemostasis","url":"https://pubmed.ncbi.nlm.nih.gov/39995753","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35981255","id":"PMC_35981255","title":"A novel F13A1 gene mutation (Arg208Pro) in a Chinese patient with factor XIII deficiency.","date":"2022","source":"Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis","url":"https://pubmed.ncbi.nlm.nih.gov/35981255","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39763522","id":"PMC_39763522","title":"Transcription Factor RUNX1 Regulates Coagulation Factor XIII-A ( F13A1 ): Decreased Platelet-Megakaryocyte F13A1 Expression and Clot Contraction in RUNX1 Haplodeficiency.","date":"2024","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39763522","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9456361","id":"PMC_9456361","title":"[Genetic polymorphisms of FABP2 and F13A1 loci in Han population].","date":"1998","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9456361","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41488895","id":"PMC_41488895","title":"Congenital factor XIII deficiency caused by F13A1 gene mutations presenting with intracranial hemorrhage: a case report.","date":"2025","source":"Frontiers in pediatrics","url":"https://pubmed.ncbi.nlm.nih.gov/41488895","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.06.03.25328938","title":"Short report: Targeted analysis of whole exome sequencing data in Indian cryptogenic stroke patients","date":"2025-06-05","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.03.25328938","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.12.17.24318561","title":"Transcription Factor RUNX1 Regulates Coagulation Factor XIII-A (<i>F13A1</i>): Decreased Platelet-Megakaryocyte<i>F13A1</i>Expression and Clot Contraction in<i>RUNX1</i>Haplodeficiency","date":"2024-12-18","source":"bioRxiv","url":"https://doi.org/10.1101/2024.12.17.24318561","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.06.631557","title":"Off-target genomic effects in MRP8-Cre driver mice complicate its use in weight gain and metabolic studies","date":"2025-01-07","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.06.631557","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.06.18.599563","title":"RUNX1 Isoforms Regulate RUNX1 and Target-Genes Differentially in Platelets-Megakaryocytes: Association with Clinical Cardiovascular Events","date":"2024-06-21","source":"bioRxiv","url":"https://doi.org/10.1101/2024.06.18.599563","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.09.11.612489","title":"PROS1 released by human lung basal cells upon SARS-CoV-2 infection facilitates epithelial cell repair and limits inflammation","date":"2024-09-13","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.11.612489","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10391209","id":"PMC_10391209","title":"Characterization of single-nucleotide polymorphisms in coding regions of human genes.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10391209","citation_count":1381,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14630798","id":"PMC_14630798","title":"Characterization of the proteins released from activated platelets leads to localization of novel platelet proteins in human atherosclerotic lesions.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14630798","citation_count":616,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12524220","id":"PMC_12524220","title":"The dynamics of thrombin formation.","date":"2003","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12524220","citation_count":387,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16335952","id":"PMC_16335952","title":"Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.","date":"2005","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/16335952","citation_count":350,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19783216","id":"PMC_19783216","title":"Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.","date":"2009","source":"The Lancet. Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19783216","citation_count":315,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9469423","id":"PMC_9469423","title":"The cytokine profile expressed by human dendritic cells is dependent on cell subtype and mode of activation.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9469423","citation_count":314,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15534175","id":"PMC_15534175","title":"Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls.","date":"2004","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15534175","citation_count":313,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7913750","id":"PMC_7913750","title":"Three-dimensional structure of a transglutaminase: human blood coagulation factor XIII.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7913750","citation_count":303,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21900206","id":"PMC_21900206","title":"A directed protein interaction network for investigating intracellular signal transduction.","date":"2011","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/21900206","citation_count":258,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"4811064","id":"PMC_4811064","title":"Amino acid sequence studies on factor XIII and the peptide released during its activation by thrombin.","date":"1974","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/4811064","citation_count":223,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25037231","id":"PMC_25037231","title":"Extracellular matrix signatures of human primary metastatic colon cancers and their metastases to liver.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/25037231","citation_count":203,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26687681","id":"PMC_26687681","title":"Cul3-KLHL20 Ubiquitin Ligase Governs the Turnover of ULK1 and VPS34 Complexes to Control Autophagy Termination.","date":"2015","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/26687681","citation_count":186,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"3026437","id":"PMC_3026437","title":"Amino acid sequence of the a subunit of human factor XIII.","date":"1986","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/3026437","citation_count":186,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28675934","id":"PMC_28675934","title":"Characterization of the Extracellular Matrix of Normal and Diseased Tissues Using Proteomics.","date":"2017","source":"Journal of proteome research","url":"https://pubmed.ncbi.nlm.nih.gov/28675934","citation_count":185,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19913121","id":"PMC_19913121","title":"Gene-centric association signals for lipids and apolipoproteins identified via the HumanCVD BeadChip.","date":"2009","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19913121","citation_count":164,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2901091","id":"PMC_2901091","title":"Characterization of the gene for the a subunit of human factor XIII (plasma transglutaminase), a blood coagulation factor.","date":"1988","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2901091","citation_count":161,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2877456","id":"PMC_2877456","title":"Primary structure of blood coagulation factor XIIIa (fibrinoligase, transglutaminase) from human placenta.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2877456","citation_count":159,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17975119","id":"PMC_17975119","title":"Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study.","date":"2007","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17975119","citation_count":142,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26324704","id":"PMC_26324704","title":"Factor XIIIa-dependent retention of red blood cells in clots is mediated by fibrin α-chain crosslinking.","date":"2015","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/26324704","citation_count":137,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2877457","id":"PMC_2877457","title":"Characterization of cDNA coding for human factor XIIIa.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2877457","citation_count":135,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9515726","id":"PMC_9515726","title":"Two non-proline cis peptide bonds may be important for factor XIII function.","date":"1998","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/9515726","citation_count":128,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21116278","id":"PMC_21116278","title":"Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease.","date":"2010","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/21116278","citation_count":127,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7920263","id":"PMC_7920263","title":"Transglutaminase factor XIII uses proteinase-like catalytic triad to crosslink macromolecules.","date":"1994","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/7920263","citation_count":126,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23381943","id":"PMC_23381943","title":"Ischemic stroke is associated with the ABO locus: the EuroCLOT study.","date":"2013","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/23381943","citation_count":125,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9550516","id":"PMC_9550516","title":"Factor XIII Val 34 Leu: a novel association with primary intracerebral hemorrhage.","date":"1998","source":"Stroke","url":"https://pubmed.ncbi.nlm.nih.gov/9550516","citation_count":115,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"23541322","id":"PMC_23541322","title":"Increased expression of factor XIII-A in patients with chronic rhinosinusitis with nasal polyps.","date":"2013","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/23541322","citation_count":112,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16635210","id":"PMC_16635210","title":"Multiple thrombophilic gene mutations rather than specific gene mutations are risk factors for recurrent miscarriage.","date":"2006","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/16635210","citation_count":109,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":26817,"output_tokens":2013,"usd":0.055323},"stage2":{"model":"claude-opus-4-6","input_tokens":5306,"output_tokens":2196,"usd":0.122145},"total_usd":0.423211,"stage1_batch_id":"msgbatch_0118RScg3WGaGkaZRtWZbtce","stage2_batch_id":"msgbatch_01Cpfzvtbj42aqp5oYZ5Te2s","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":40939,"output_tokens":3363,"usd":0.086631},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":7035,"output_tokens":2836,"usd":0.159112}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2019,\n      \"finding\": \"ZED3197, a peptidomimetic inhibitor, potently and selectively inhibits FXIIIa (F13A1) transglutaminase activity, blocking fibrin crosslinking in biochemical assays and thromboelastometry, and reducing clot weight in a rabbit venous stasis model without prolonging bleeding time.\",\n      \"method\": \"Transamidation and isopeptidase in vitro assays, rotational thromboelastometry in whole blood, in vivo rabbit venous stasis model\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro enzymatic assay with selectivity panel, confirmed in vivo with functional readouts\",\n      \"pmids\": [\"31578814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"The first 951 bp of F13A1 intron 1 regulates F13A1 gene expression; a variant IVS1+12C>A eliminates an Sp1 binding site (confirmed by EMSA), reduces Sp1-driven transcription, and leads to decreased FXIII-A expression.\",\n      \"method\": \"Luciferase reporter assay in U937 cells, electrophoretic mobility shift assay (EMSA), Sp1 co-transfection\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal methods (reporter, EMSA, co-transfection) in a single study\",\n      \"pmids\": [\"21512576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"F13A1 directly interacts with pyruvate kinase M2 (PKM2), promoting PKM2 dimerization in a process enhanced by intracellular calcium; dimerized PKM2 translocates to the nucleus and upregulates IL-1β expression via the PKM2/HIF1A axis, driving pro-inflammatory macrophage activation and the Warburg effect in MASH.\",\n      \"method\": \"Co-IP/pulldown (F13A1–PKM2 interaction), F13A1 silencing in vivo and in vitro, pharmacologic PKM2 activation (DASA-58), single-nucleus transcriptomics validation\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct protein interaction shown with functional rescue, but single lab study\",\n      \"pmids\": [\"41417477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Transcription factor RUNX1 directly regulates F13A1 transcription in megakaryocytes and platelets; RUNX1 overexpression increases and siRNA knockdown reduces F13A1 promoter activity and protein; loss of F13A1 impairs clot contraction, reduces FXIII-A surface expression, decreases myosin light chain phosphorylation, and reduces αIIbβ3 activation.\",\n      \"method\": \"Promoter-luciferase assay, siRNA knockdown in HEL cells and CD34+-derived megakaryocytes, clot contraction assay, flow cytometry (PAC1 binding), phosphorylation assays\",\n      \"journal\": \"Research and practice in thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods across primary cells and cell lines, functional phenotype in patient platelets and knockdown models\",\n      \"pmids\": [\"39995753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"In silico structural analysis of eight novel F13A1 missense mutations mapped onto crystal structure models showed that core domain mutations (e.g., Pro166Leu, Arg171Gln, His342Tyr) directly influence the catalytic triad, while mutations in other domains affect activation peptide cleavage or barrel domain integrity, providing structural basis for mild FXIII-A deficiency.\",\n      \"method\": \"In silico structural analysis using X-ray crystallographic PDB models of activated and non-activated FXIII-A\",\n      \"journal\": \"Annals of hematology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 4 — computational structural prediction only, no in vitro functional validation\",\n      \"pmids\": [\"24889649\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"The G273V mutation in the core domain of FXIII-A is predicted by molecular modelling to cause steric clashes with surrounding residues, resulting in structural instability; compound heterozygosity with W187X (nonsense) causes severe FXIII-A deficiency with undetectable activity by three functional assays and absent antigen by four immunological assays.\",\n      \"method\": \"Functional assays (ammonia release, amine incorporation), immunological assays (ELISA), mixing test, dosing test, DNA sequencing, molecular modelling\",\n      \"journal\": \"Haemophilia : the official journal of the World Federation of Hemophilia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2/3 — functional biochemical assays confirm loss of activity; structural mechanism is computational\",\n      \"pmids\": [\"24286209\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"F13A1 expression in human adipose tissue and adipocyte-enriched fractions increases with acquired excess weight and associates with adipocyte hypertrophy, reduced circulating adiponectin, and transcriptomic pathways of inflammation, cell stress, and extracellular matrix remodeling.\",\n      \"method\": \"Affymetrix full transcriptome mRNA analysis in weight-discordant monozygotic twins, whole transcriptome-wide association study (TWAS), DXA and MRI body composition\",\n      \"journal\": \"International journal of obesity (2005)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — controlled human twin study with transcriptomics but no direct loss-of-function experiment\",\n      \"pmids\": [\"33221826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Accelerated processing/cleavage of F13A1 in platelets of lung cancer patients generates a 55 kDa fragment; this fragment correlates with plasma plasmin-α2-antiplasmin complex and D-dimer levels, suggesting enhanced fibrinolytic degradation contributes to hypercoagulability.\",\n      \"method\": \"2D-DIGE platelet proteomics, correlation analysis with plasma fibrinolysis markers\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — unbiased proteomics with functional correlation, single lab study\",\n      \"pmids\": [\"34066760\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"F13A1 encodes the A-subunit of coagulation Factor XIII, a transglutaminase that covalently crosslinks fibrin to stabilize clots; its expression in megakaryocytes and platelets is transcriptionally regulated by RUNX1 (via direct promoter binding), and in macrophages it promotes pro-inflammatory activation by interacting with PKM2 to drive PKM2 dimerization, nuclear translocation, and IL-1β expression via the HIF1A axis; catalytic activity is executed through its transglutaminase domain (which can be selectively inhibited by ZED3197), and intron 1 sequences containing an Sp1 site modulate its transcriptional output.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1974,\n      \"finding\": \"Factor XIII A-subunit is activated by thrombin cleavage, releasing an activation peptide from the amino terminus.\",\n      \"method\": \"Amino acid sequence analysis of tryptic peptides and activation peptide isolation\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct biochemical sequencing of activation peptide, foundational study with 223 citations\",\n      \"pmids\": [\"4811064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"The A subunit of human factor XIII (F13A1) is a 731-amino acid protein containing a catalytic triad active site with the sequence Tyr-Gly-Gln-Cys-Trp, identical to that of tissue transglutaminase; thrombin cleaves it at two sites — activation at the N-terminus and inactivation after Lys-513.\",\n      \"method\": \"cDNA cloning from human placenta library, amino acid sequencing by automated sequenator, cyanogen bromide peptide analysis\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete primary structure determined by cDNA + direct protein sequencing, replicated by two independent labs in same year\",\n      \"pmids\": [\"3026437\", \"2877456\", \"2877457\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The F13A1 gene spans >160 kb and contains 15 exons separated by 14 introns; functionally distinct regions (activation peptide, active-site cysteine, calcium-binding regions, thrombin inactivation site) are each encoded by separate exons, suggesting domain-level structural organization.\",\n      \"method\": \"Genomic library screening, restriction mapping, Southern blotting, DNA sequencing\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — complete gene structure determination with functional domain mapping\",\n      \"pmids\": [\"2901091\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The three-dimensional crystal structure of human factor XIII zymogen at 2.8-Å resolution reveals that each A-subunit chain folds into four sequential domains; a catalytic triad (Cys-His-Asp) reminiscent of cysteine proteases is located in the core domain; the amino-terminal activation peptide of each subunit crosses the dimer interface and partially occludes the catalytic cavity of the second subunit, preventing substrate access in the zymogen. Thrombin cleavage and calcium binding are proposed to open the active site.\",\n      \"method\": \"X-ray crystallography of recombinant human factor XIII at 2.8-Å resolution\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with mechanistic interpretation, 303 citations\",\n      \"pmids\": [\"7913750\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Factor XIII uses a cysteine proteinase-like catalytic triad (Cys-His-Asp) to catalyze transglutaminase crosslinking reactions; structural comparison shows active site architecture is shared with cysteine proteinases despite different overall fold, suggesting convergent or divergent evolution.\",\n      \"method\": \"X-ray crystallography, structural comparison of active site residues\",\n      \"journal\": \"Protein science : a publication of the Protein Society\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure with active-site mechanistic analysis, 126 citations\",\n      \"pmids\": [\"7920263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The refined 2.1-Å crystal structure of human cellular factor XIII zymogen identifies two non-proline cis peptide bonds: one between Arg310 and Tyr311 near the active site cysteine (Cys314), and one between Gln425 and Phe426 at the dimerization interface, suggesting these structural elements are important for catalytic function and dimer stability.\",\n      \"method\": \"X-ray crystallography refined to R-factor 18.3% at 2.1-Å resolution\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — high-resolution crystal structure with structural functional interpretation, 128 citations\",\n      \"pmids\": [\"9515726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"An intronic mutation in intron 1 of F13A1 (Int1+12C>A) causes mild FXIII deficiency by reducing protein binding at an Sp1 site; Sp1 was shown to regulate F13A1 transcription via the first 951 bp of intron 1, and co-transfection with Sp1 restored expression, establishing intron 1 as a regulatory element.\",\n      \"method\": \"Luciferase reporter assays in U937 cells, electrophoretic mobility shift assay (EMSA), Sp1 co-transfection, direct sequencing\",\n      \"journal\": \"Journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal in vitro methods (reporter + EMSA + co-transfection), single lab\",\n      \"pmids\": [\"21512576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"FXIIIa-dependent retention of red blood cells in contracting clots is mediated specifically by fibrin α-chain crosslinking; FXIIIa does not directly crosslink RBCs to fibrin. RBC retention was lost when α-chain crosslinking sites were absent but not when γ-chain crosslinking sites were absent, and was independent of FXIIIa substrates α2-antiplasmin, thrombin-activatable fibrinolysis inhibitor, or fibronectin.\",\n      \"method\": \"Real-time microscopy of clot contraction, fibrin band-shift assays, flow cytometry, clots from mice deficient in specific FXIIIa substrates, FXIIIa inhibition at concentrations selectively blocking α- vs γ-chain crosslinking\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple orthogonal approaches including genetic knockouts and selective inhibition, mechanistic dissection of crosslinking specificity, 137 citations\",\n      \"pmids\": [\"26324704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ZED3197, a peptidomimetic inhibitor, potently and selectively inhibits FXIIIa transglutaminase activity (transamidation and isopeptidase assays) with selectivity over other human transglutaminases; it inhibits fibrin crosslinking in whole blood thromboelastometry and reduces clot weight in a rabbit venous stasis model without prolonging bleeding time, demonstrating that FXIIIa inhibition can dissociate antithrombotic effect from bleeding risk.\",\n      \"method\": \"Transamidation and isopeptidase biochemical assays, rotational thromboelastometry in whole human blood, rabbit venous stasis/reperfusion in vivo model\",\n      \"journal\": \"Journal of thrombosis and haemostasis : JTH\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — in vitro enzymatic assays plus in vivo pharmacological validation, multiple methods\",\n      \"pmids\": [\"31578814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RUNX1 transcription factor directly regulates F13A1 transcription in megakaryocytes and platelets; RUNX1 overexpression increased and siRNA knockdown decreased F13A1 promoter activity and protein. F13A1 knockdown impaired clot contraction, reduced FXIII-A surface expression, decreased myosin light chain phosphorylation, and reduced αIIbβ3 activation (PAC1 binding), establishing F13A1 as a downstream effector of RUNX1 in platelet clot contraction.\",\n      \"method\": \"Promoter luciferase assays in HEL cells, siRNA knockdown of RUNX1 and F13A1, clot contraction assays, flow cytometry (surface FXIII-A, PAC1), myosin light chain phosphorylation assays, human CD34+-derived megakaryocytes\",\n      \"journal\": \"Research and practice in thrombosis and haemostasis\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (reporter, KD, functional clot assay, phosphorylation) across cell lines and primary megakaryocytes\",\n      \"pmids\": [\"39995753\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"F13A1 in macrophages directly interacts with pyruvate kinase M2 (PKM2), promoting PKM2 dimerization in a calcium-dependent manner; dimerized PKM2 translocates to the nucleus and upregulates IL-1β via the PKM2/HIF1A axis, driving macrophage pro-inflammatory activation and the Warburg effect in MASH. F13A1 expression in macrophages is induced by lipid-stressed hepatocytes through a sphingosine-1-phosphate (S1P)-dependent mechanism.\",\n      \"method\": \"Co-immunoprecipitation (F13A1-PKM2 interaction), siRNA silencing of F13A1 in vivo and in vitro, nuclear translocation assays, IL-1β expression assays, PKM2 activator (DASA-58) pharmacological rescue, single-nucleus transcriptomic datasets, murine MASH models\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional rescue with pharmacological PKM2 activator and in vivo silencing, single lab\",\n      \"pmids\": [\"41417477\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Factor XIIIa is expressed in CD14+-derived dendritic cells but not in CD1a+-derived dendritic cells, establishing lineage-specific expression of F13A1 within the dendritic cell compartment differentiated from CD34+ progenitors.\",\n      \"method\": \"Semiquantitative RT-PCR and phenotypic analysis of two DC subpopulations generated in vitro from CD34+ progenitors\",\n      \"journal\": \"Journal of immunology (Baltimore, Md. : 1950)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — RT-PCR-based localization with cellular phenotype characterization, 314 citations but single method for F13A1 specifically\",\n      \"pmids\": [\"9469423\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FXIII-A is overexpressed in nasal polyps and is produced predominantly by CD68+/CD163+ M2 macrophages; FXIII-A levels correlate with M2 macrophage markers, implicating macrophage-derived FXIII-A in excessive fibrin crosslinking and tissue remodeling in chronic rhinosinusitis with nasal polyps.\",\n      \"method\": \"Real-time PCR, ELISA, immunohistochemistry, immunofluorescence co-staining with macrophage markers in human sinonasal tissue\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — multiple protein detection methods establishing cellular source, no functional KO/KD experiment, 112 citations\",\n      \"pmids\": [\"23541322\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"F13A1 encodes the A-subunit of coagulation factor XIII, a transglutaminase zymogen that circulates as an A2B2 tetramer; upon thrombin cleavage of its activation peptide and calcium binding, the active site Cys314 (within a Cys-His-Asp catalytic triad structurally analogous to cysteine proteases) is exposed, enabling covalent γ-glutamyl-ε-lysyl crosslinking of fibrin (primarily via α-chain crosslinking to retain RBCs in clots), and the protein also functions intracellularly in macrophages and platelets where it interacts with PKM2 to drive inflammatory signaling and is transcriptionally regulated by RUNX1 in megakaryocytes/platelets to support clot contraction.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"F13A1 encodes the catalytic A-subunit of coagulation Factor XIII, a transglutaminase that covalently crosslinks fibrin to stabilize blood clots and supports platelet-mediated clot contraction. Its transglutaminase activity, executed through a catalytic triad in the core domain, can be selectively blocked by the peptidomimetic inhibitor ZED3197, which reduces clot weight in vivo without prolonging bleeding time [PMID:31578814]. Transcription of F13A1 is driven by RUNX1 in megakaryocytes—where loss of F13A1 impairs integrin αIIbβ3 activation and myosin light chain phosphorylation—and is modulated by an Sp1-binding element in intron 1 [PMID:39995753, PMID:21512576]. Beyond hemostasis, F13A1 in macrophages directly interacts with PKM2, promoting its dimerization and nuclear translocation to upregulate IL-1β via the HIF1α axis, linking F13A1 to pro-inflammatory metabolic reprogramming [PMID:41417477].\",\n  \"teleology\": [\n    {\n      \"year\": 2011,\n      \"claim\": \"How F13A1 transcription is regulated was unknown; identification of an Sp1-dependent regulatory element in intron 1 established that non-coding sequences directly modulate FXIII-A expression levels.\",\n      \"evidence\": \"Luciferase reporter assays, EMSA, and Sp1 co-transfection in U937 cells\",\n      \"pmids\": [\"21512576\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether additional transcription factors cooperate with Sp1 at this locus\",\n        \"Whether the intron 1 element is active in all F13A1-expressing cell types\"\n      ]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Whether specific missense mutations cause FXIII-A deficiency through structural disruption was unclear; compound heterozygous G273V/W187X mutations were shown to abolish both antigen and activity, confirming that core-domain integrity is essential for protein stability and catalytic function.\",\n      \"evidence\": \"Functional assays (ammonia release, amine incorporation), ELISA, and molecular modelling on patient samples\",\n      \"pmids\": [\"24286209\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No recombinant expression of G273V to confirm structural mechanism independent of the nonsense allele\",\n        \"Whether the structural instability leads to ER-associated degradation or misfolding\"\n      ]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Whether the transglutaminase activity of FXIIIa could be pharmacologically targeted without impairing hemostasis was untested; ZED3197 demonstrated selective inhibition of fibrin crosslinking and reduced venous thrombus weight in vivo without bleeding prolongation, validating FXIIIa as a druggable antithrombotic target.\",\n      \"evidence\": \"In vitro transamidation/isopeptidase assays with selectivity panel, thromboelastometry in whole blood, rabbit venous stasis model\",\n      \"pmids\": [\"31578814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Efficacy and safety in arterial thrombosis models not tested\",\n        \"Whether long-term inhibition affects wound healing or other FXIII-dependent processes\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Whether F13A1 has roles outside hemostasis in metabolic tissues was unknown; upregulation of F13A1 in adipose tissue with excess weight, correlating with adipocyte hypertrophy and inflammatory transcriptomic signatures, implicated it in obesity-associated tissue remodeling.\",\n      \"evidence\": \"Transcriptomic analysis in weight-discordant monozygotic twins with body composition imaging\",\n      \"pmids\": [\"33221826\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"No loss-of-function experiment in adipocytes to establish causality\",\n        \"Whether adipose F13A1 acts via transglutaminase activity or a non-enzymatic mechanism\"\n      ]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"How platelet F13A1 is altered in cancer-associated hypercoagulability was unexplored; identification of accelerated F13A1 cleavage generating a 55 kDa fragment in lung cancer patient platelets, correlated with fibrinolysis markers, linked F13A1 processing to the prothrombotic state.\",\n      \"evidence\": \"2D-DIGE platelet proteomics with correlation to plasma D-dimer and plasmin–α2-antiplasmin complexes\",\n      \"pmids\": [\"34066760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Protease responsible for the 55 kDa fragment not identified\",\n        \"Functional consequence of the fragment on clot stability not directly tested\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"What transcription factor drives F13A1 in the megakaryocyte lineage was unresolved; RUNX1 was shown to directly bind and activate the F13A1 promoter, and loss of F13A1 impaired clot contraction, integrin activation, and myosin light chain phosphorylation, establishing a RUNX1–F13A1 axis in platelet function beyond fibrin crosslinking.\",\n      \"evidence\": \"Promoter-luciferase assays, siRNA in HEL cells and CD34+-derived megakaryocytes, clot contraction assays, PAC1 flow cytometry\",\n      \"pmids\": [\"39995753\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether RUNX1 cooperates with Sp1 at the intron 1 element\",\n        \"Mechanism by which intracellular FXIII-A influences myosin light chain phosphorylation\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Whether F13A1 has a direct signaling role in macrophages was unknown; demonstration that F13A1 physically interacts with PKM2 to drive its dimerization and nuclear translocation, activating IL-1β via HIF1α, established a non-hemostatic, pro-inflammatory function for F13A1 in metabolic liver disease.\",\n      \"evidence\": \"Co-IP/pulldown, F13A1 silencing in vivo and in vitro, pharmacologic PKM2 rescue (DASA-58), single-nucleus transcriptomics\",\n      \"pmids\": [\"41417477\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether the F13A1–PKM2 interaction requires transglutaminase catalytic activity or is non-enzymatic\",\n        \"Whether this mechanism operates in tissue macrophages beyond the liver\",\n        \"Single-lab finding awaiting independent replication\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include whether F13A1's intracellular platelet functions (integrin activation, clot contraction) depend on its transglutaminase activity or on a scaffolding role, and the structural basis by which F13A1 promotes PKM2 dimerization.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structure of F13A1–PKM2 complex\",\n        \"Catalytic vs. non-catalytic intracellular functions not systematically dissected\",\n        \"Role of F13A1 in immune cells beyond macrophages unexplored\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 5]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 3, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PKM2\",\n      \"RUNX1\",\n      \"SP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"F13A1 encodes the catalytic A-subunit of coagulation factor XIII, a transglutaminase zymogen that circulates as an A₂ homodimer and is activated by thrombin cleavage of an N-terminal activation peptide followed by calcium-dependent conformational opening of a Cys-His-Asp catalytic triad structurally analogous to cysteine proteases [PMID:4811064, PMID:7913750, PMID:7920263]. Activated FXIIIa catalyzes γ-glutamyl-ε-lysyl isopeptide crosslinking of fibrin, with α-chain crosslinking specifically required for red blood cell retention during clot contraction, while selective pharmacological inhibition of FXIIIa reduces thrombus formation without prolonging bleeding time [PMID:26324704, PMID:31578814]. In megakaryocytes and platelets, F13A1 is transcriptionally regulated by RUNX1 and functions as a downstream effector supporting integrin αIIbβ3 activation and myosin light chain phosphorylation during clot contraction [PMID:39995753]. Beyond hemostasis, intracellular F13A1 in macrophages interacts with PKM2 in a calcium-dependent manner, promoting PKM2 dimerization and nuclear translocation to drive IL-1β expression via the HIF1α axis during pro-inflammatory activation [PMID:41417477].\",\n  \"teleology\": [\n    {\n      \"year\": 1974,\n      \"claim\": \"Establishing that factor XIII is a thrombin-activated zymogen resolved how transglutaminase activity is regulated in coagulation, identifying the activation peptide as the gating element.\",\n      \"evidence\": \"Amino acid sequencing of tryptic peptides and isolation of activation peptide from purified factor XIII\",\n      \"pmids\": [\"4811064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which activation peptide removal triggers catalytic competence was unknown\", \"Calcium requirement not yet defined\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Complete primary structure determination revealed F13A1 as a 731-residue transglutaminase sharing the Tyr-Gly-Gln-Cys-Trp active-site motif with tissue transglutaminase, placing it firmly in the transglutaminase family and identifying a second thrombin inactivation site at Lys-513.\",\n      \"evidence\": \"cDNA cloning from human placenta, automated amino acid sequencing, cyanogen bromide peptide analysis by two independent laboratories\",\n      \"pmids\": [\"3026437\", \"2877456\", \"2877457\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Three-dimensional structure and spatial arrangement of active-site residues unknown\", \"Functional significance of inactivation cleavage at Lys-513 not tested\"]\n    },\n    {\n      \"year\": 1988,\n      \"claim\": \"Mapping the gene structure showed that functionally distinct domains (activation peptide, catalytic cysteine, calcium-binding region) reside on separate exons, providing a framework for understanding disease-causing mutations and evolutionary modularity.\",\n      \"evidence\": \"Genomic library screening, restriction mapping, Southern blotting, and DNA sequencing of the >160 kb F13A1 locus\",\n      \"pmids\": [\"2901091\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter and transcriptional regulatory elements not characterized\", \"Intronic regulatory sequences not explored\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Crystal structures of the zymogen resolved how the activation peptide from one subunit crosses the dimer interface to occlude the partner's catalytic cavity, explaining why thrombin cleavage and calcium are both required for activation, and revealed a Cys-His-Asp catalytic triad convergently similar to cysteine proteases.\",\n      \"evidence\": \"X-ray crystallography at 2.8 Å resolution of recombinant human factor XIII zymogen with structural comparison to cysteine proteinases\",\n      \"pmids\": [\"7913750\", \"7920263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure of the fully activated enzyme or enzyme–substrate complex\", \"Conformational pathway from zymogen to active form not visualized\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Higher-resolution refinement identified non-proline cis peptide bonds near the active site and dimer interface, pinpointing structural features critical for catalysis and A₂ dimer stability, while parallel studies showed lineage-restricted expression in CD14⁺-derived dendritic cells, broadening F13A1 function beyond coagulation.\",\n      \"evidence\": \"X-ray crystallography at 2.1 Å resolution; RT-PCR-based lineage analysis of DC subpopulations from CD34⁺ progenitors\",\n      \"pmids\": [\"9515726\", \"9469423\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional role of cis peptide bonds not tested by mutagenesis\", \"Function of F13A1 in dendritic cells not determined\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Identification of Sp1-dependent transcriptional regulation through intron 1 provided the first mechanistic explanation for how non-coding mutations cause mild FXIII deficiency.\",\n      \"evidence\": \"Luciferase reporter assays in U937 cells, EMSA, and Sp1 co-transfection rescue for an Int1+12C>A patient mutation\",\n      \"pmids\": [\"21512576\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No chromatin-level or in vivo confirmation of Sp1 regulation\", \"Other intronic regulatory elements not surveyed\", \"Single patient mutation studied\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrating that M2 (CD68⁺/CD163⁺) macrophages are the principal cellular source of FXIII-A in inflamed tissue linked the transglutaminase to tissue remodeling beyond plasma clot formation.\",\n      \"evidence\": \"Real-time PCR, ELISA, immunohistochemistry, and co-immunofluorescence in human nasal polyp tissue\",\n      \"pmids\": [\"23541322\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No knockdown or knockout to prove functional contribution in tissue remodeling\", \"Mechanism of FXIII-A action in tissue not defined\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Dissecting FXIIIa substrate specificity showed that fibrin α-chain crosslinking — not γ-chain crosslinking or other substrates — is the specific mechanism retaining red blood cells in contracting clots, redefining the functional hierarchy among FXIIIa crosslinking activities.\",\n      \"evidence\": \"Real-time clot contraction microscopy, selective FXIIIa inhibition, flow cytometry, and clots from mice lacking individual FXIIIa substrates\",\n      \"pmids\": [\"26324704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for α-chain crosslinking's unique role in RBC retention unknown\", \"Whether α-chain crosslinking specificity is relevant in arterial versus venous thrombi not addressed\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Pharmacological proof-of-concept with the selective inhibitor ZED3197 demonstrated that FXIIIa transglutaminase activity can be targeted to reduce venous thrombosis without increasing bleeding, separating antithrombotic efficacy from hemostatic risk.\",\n      \"evidence\": \"Biochemical transamidation/isopeptidase assays, whole-blood thromboelastometry, rabbit venous stasis model\",\n      \"pmids\": [\"31578814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No data in arterial thrombosis models\", \"Long-term safety and wound healing impact not assessed\", \"Mechanism explaining preserved hemostasis despite FXIIIa inhibition not fully elucidated\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Two studies expanded F13A1's mechanistic scope: RUNX1 was identified as a direct transcriptional regulator of F13A1 in megakaryocytes linking it to integrin activation and clot contraction, while in macrophages F13A1 was shown to directly interact with PKM2 to drive pro-inflammatory reprogramming via the PKM2/HIF1α/IL-1β axis.\",\n      \"evidence\": \"Promoter reporters, siRNA knockdown of RUNX1/F13A1, clot contraction and PAC1/MLC phosphorylation assays in HEL cells and primary megakaryocytes; Co-IP of F13A1–PKM2, DASA-58 pharmacological rescue, in vivo silencing in murine MASH models\",\n      \"pmids\": [\"39995753\", \"41417477\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"RUNX1-F13A1 axis not validated in vivo with RUNX1-deficient platelets\", \"F13A1–PKM2 interaction awaits structural characterization\", \"Whether F13A1 transglutaminase activity or a scaffolding role drives PKM2 dimerization is unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"No structure of fully activated FXIIIa in complex with fibrin or PKM2 substrates exists, and the intracellular activation mechanism of F13A1 in platelets and macrophages (in the absence of thrombin) remains undefined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No activated FXIIIa–substrate co-crystal structure\", \"Thrombin-independent intracellular activation mechanism unknown\", \"Relative contribution of enzymatic versus scaffolding functions in immune cells not delineated\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 3, 4, 7, 8]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 3, 4, 7, 8]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 7, 8]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [9, 10]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-109582\", \"supporting_discovery_ids\": [0, 1, 3, 7, 8, 9]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [10, 11, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"PKM2\",\n      \"RUNX1\",\n      \"SP1\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}